|
A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease. |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; Genentech; Kite, a Gilead company; Pharmacyclics; Sanofi; Velos |
Research Funding - Pharmacyclics |
Patents, Royalties, Other Intellectual Property - Pharmacyclics |
Travel, Accommodations, Expenses - Pharmacyclics; Sanofi |
|
|
Consulting or Advisory Role - Janssen; Theracos, Inc. |
Research Funding - Janssen; Theracos, Inc. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Allergan; Gilead Sciences; Novartis; Pfizer |
Research Funding - Gilead Sciences; Mundipharma; Sanofi |
|
|
No Relationships to Disclose |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
Consulting or Advisory Role - Alexion Pharmaceuticals; Cellerant |
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Mesoblast |
|
|
Employment - Pharmacyclics |
Leadership - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Research Funding - Pharmacyclics (Inst) |
Travel, Accommodations, Expenses - Therakos |